NEW YORK, Sept. 5 - Bio-Quant has created a new division designed to offer screening technology for G protein-coupled receptors, the company said on Wednesday.
GPCRs function as the delivery mechanism for more than 50 percent of all drugs currently on the market. To facilitate the discovery of additional GPCRs that might serve as drug targets, Bio-Quant’s new business unit will provide platforms that screen for cell motility and GPCR activation.
“These two platforms for drug discovery will allow biotechnology/pharmaceutical companies to screen their compound libraries much faster and cheaper, enabling them to get to market much sooner,” Bio-Quant CEO Bassam Damaj said in a statement.
As part of the cell motility, or chemotaxis, platform, San Diego-based Bio-Quant’s new division will offer leakage-resistant fluorescent dyes, chemotaxis assays, and imaging devices with liquid-handling capabilities.
The cell activation platform, also called the intracellular calcium mobilization measurement platform, includes fluorescent CalciDyes and a microplate imaging device.